Siji Chen

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 7

Top Topics

Atopic Dermatitis

Chronic Obstructive Pulmonary Disease

Multiple Myeloma

Top Venues

Human vaccines & immunotherapeutics

Drug design, development and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Jie Chen, Siji Chen, Xia Wu, Xiaoyun Jiang, Yongdong Wang, Hao Cheng
The complicated use of dupilumab in the treatment of atypical generalized pemphigus Erythematous: A report of two cases. Human vaccines & immunotherapeutics 19 (1) (2023)
Jie Chen, Siji Chen, Xia Wu, Xiaoyun Jiang, Yongdong Wang, Hao Cheng
The complicated use of dupilumab in the treatment of atypical generalized pemphigus Erythematous: A report of two cases. Human vaccines & immunotherapeutics 19 (1) (2023)
Jie Chen, Siji Chen, Xia Wu, Xiaoyun Jiang, Yongdong Wang, Hao Cheng
The complicated use of dupilumab in the treatment of atypical generalized pemphigus Erythematous: A report of two cases. Human vaccines & immunotherapeutics 19 (1) (2023)
Jie Chen, Siji Chen, Xia Wu, Xiaoyun Jiang, Yongdong Wang, Hao Cheng
The complicated use of dupilumab in the treatment of atypical generalized pemphigus Erythematous: A report of two cases. Human vaccines & immunotherapeutics 19 (1) (2023)
Can Zhou, Chunting Hua, Qichang Liang, Mus'ab Al Rudaisat, Siji Chen, Yinjing Song, Jiang Zhu, Hao Cheng
0.5-5% Supramolecular Salicylic Acid Hydrogel is Safe for Long-Term Topical Application and Improves the Expression of Genes Related to Skin Barrier Homeostasis in Mice Models. Drug design, development and therapy 17 (2023)
Jie Chen, Siji Chen, Xia Wu, Xiaoyun Jiang, Yongdong Wang, Hao Cheng
The complicated use of dupilumab in the treatment of atypical generalized pemphigus Erythematous: A report of two cases. Human vaccines & immunotherapeutics (2023)
Jie Chen, Siji Chen, Xia Wu, Xiaoyun Jiang, Yongdong Wang, Hao Cheng
The complicated use of dupilumab in the treatment of atypical generalized pemphigus Erythematous: A report of two cases. Human vaccines & immunotherapeutics 19 (1) (2023)